Cargando…

Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy

BACKGROUND: At present, immunotherapy has become an important treatment for lung cancer. With the widespread use of immune checkpoint inhibitors (ICIs), we must be strict with the emergence of immune related adverse events (irAEs). There are also some patients who do not respond to immunotherapy. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Ni, Yi, Ye, Cao, Wen, Fu, Xiao, Mei, Nan, Li, Chunli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449836/ https://www.ncbi.nlm.nih.gov/pubmed/36091125 http://dx.doi.org/10.3389/fonc.2022.923531

Ejemplares similares

Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022)

Construction and Evaluation of Clinical Prediction Model for Immunotherapy-related Adverse Events and Clinical Benefit in Cancer Patients Receiving Immune Checkpoint Inhibitors Based on Serum Cytokine Levels
por: Zhao, Ni, et al.
Publicado: (2023)

Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study
por: Morimoto, Kenji, et al.
Publicado: (2021)

Editorial: Immune-Related Adverse Events for Patients With Lung Cancer
por: Yang, Ruoning, et al.
Publicado: (2022)

Neurologic adverse events of cancer immunotherapy
por: de Brito, Marcelo Houat
Publicado: (2022)

Editorial: Tumor immune microenvironment topographies for prediction and evaluation: unlock the mystery of the therapeutic effects and adverse events of tumor immunotherapy
por: Yin, Xiaoran, et al.
Publicado: (2023)

Editorial: Immune-related adverse events for patients with lung cancer-volume II
por: Wang, Yusha, et al.
Publicado: (2023)

Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer
por: Hou, Wanting, et al.
Publicado: (2021)

Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer
por: Tao, Ye, et al.
Publicado: (2023)

Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis
por: Hu, Jiexuan, et al.
Publicado: (2021)

Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer
por: Burke, Michael, et al.
Publicado: (2021)

Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management
por: Liu, Ya, et al.
Publicado: (2021)

Editorial: Optimizing outcomes and addressing adversities of immunotherapy in lung cancer
por: Al-Rajabi, Taiseer, et al.
Publicado: (2023)

Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment
por: Zheng, Xiaohu, et al.
Publicado: (2021)

Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
por: Albarrán-Artahona, Víctor, et al.
Publicado: (2022)

Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
por: Wang, Donghui, et al.
Publicado: (2021)

Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
por: Daniello, Lea, et al.
Publicado: (2021)

Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis
por: Sun, Qian, et al.
Publicado: (2022)

Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
por: Soria, Anna, et al.
Publicado: (2022)

Immune-Related Adverse Events: A Case-Based Approach
por: Connolly, Caoilfhionn, et al.
Publicado: (2019)

Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors
por: Rose, Lynn M., et al.
Publicado: (2021)

Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study
por: Egami, Saeka, et al.
Publicado: (2021)

Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors
por: Schindler, Hannah, et al.
Publicado: (2022)

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis
por: Anpalakhan, Shobana, et al.
Publicado: (2023)

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
por: Sayer, Michael R., et al.
Publicado: (2023)

Arthralgia adverse events due to immune-checkpoint inhibitors for lung cancer patients: a systematic review and meta-analysis
por: Zou, Defang, et al.
Publicado: (2023)

Risk factors for cardiovascular adverse events from immune checkpoint inhibitors
por: Luo, Lingli, et al.
Publicado: (2023)

Baseline risk factors associated with immune related adverse events and atezolizumab
por: Madjar, Katrin, et al.
Publicado: (2023)

Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2
por: Ragoonanan, Dristhi, et al.
Publicado: (2021)

The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer
por: Coschi, Courtney H., et al.
Publicado: (2021)

Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis
por: Yang, Wenhan, et al.
Publicado: (2020)

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
por: Bastacky, Melissa L., et al.
Publicado: (2021)

Peripheral absolute eosinophil count identifies the risk of serious immune-related adverse events in non-small cell lung cancer
por: Wu, Yan, et al.
Publicado: (2022)

Serum cytokine levels and other associated factors as possible immunotherapeutic targets and prognostic indicators for lung cancer
por: Zhao, Yinghao, et al.
Publicado: (2023)

Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma
por: Lacouture, Mario E., et al.
Publicado: (2020)

Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review
por: Ouyang, Tao, et al.
Publicado: (2021)

Trends in immune-related adverse events for colorectal cancer: A bibliometric analysis
por: Cui, Jin, et al.
Publicado: (2022)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis
por: Zhao, Zhe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vd8vka92j3a0s66jv4uhf7ut00